Abstract: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the severe toxicological effects of environmental pollutants like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), including immunotoxicity, hepatotoxicity, and wasting syndrome. CH-223191 is a novel, synthetic small molecule identified as a potent and specific AhR antagonist. Unlike naturally occurring AhR antagonists such as flavonoids, CH-223191 acts as a pure antagonist devoid of partial agonist or estrogenic activity. It effectively blocks TCDD-induced AhR nuclear translocation, DNA binding, and subsequent cytochrome P450 induction, thereby preventing TCDD-induced toxicity in vivo. Furthermore, CH-223191 has proven to be a valuable molecular tool in developmental biology, revealing that basal AhR signaling is essential for cardiovascular homeostasis and cardiomyocyte differentiation. This review synthesizes current knowledge on the pharmacological activity, molecular mechanisms, and future therapeutic potential of CH-223191 based on recent literature.
1. Introduction
The aryl hydrocarbon receptor (AhR) is a cytosolic basic helix-loop-helix transcription factor that plays a central role in mediating the toxic effects of environmental contaminants, most notably 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [1]. Exposure to TCDD leads to a wide array of adverse health outcomes, including lethality, tumor promotion, immunotoxicity, teratogenicity, and endocrine disruption [1]. Upon ligand binding, the AhR translocates to the nucleus, dimerizes with the AhR nuclear translocator (ARNT), and binds to dioxin-responsive elements (DREs) to drive the transcription of target genes, such as cytochrome P450 enzymes (e.g., CYP1A1, CYP1A2, CYP1B1) [1]. The chronic induction of these enzymes can generate highly reactive electrophilic metabolites and oxygen radicals, culminating in cellular damage and cancer [1].
Given the central role of AhR in dioxin-induced pathology, the development of specific AhR antagonists is a highly attractive strategy for chemoprevention. While several naturally occurring compounds (e.g., flavone, resveratrol) exhibit AhR antagonistic properties, their therapeutic utility is often limited by partial agonistic effects at higher concentrations and off-target interactions with estrogen receptors [1]. To overcome these limitations, high-throughput screening efforts identified CH-223191 (2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide), a novel synthetic compound that potently and specifically antagonizes the AhR without exhibiting agonist-like or estrogenic activities [1]. Beyond toxicology, CH-223191 has also emerged as a critical tool for investigating the physiological and developmental roles of AhR, particularly in embryonic stem cell differentiation and cardiomyogenesis [2].
2. Pharmacological Activity
CH-223191 exhibits robust pharmacological activity both ex vivo and in vivo by counteracting the effects of AhR activation. In cultured human hepatoma (HepG2) cells, CH-223191 dose-dependently inhibits TCDD-induced expression of CYP1A1 mRNA and protein, as well as cytochrome P450 enzymatic activity (measured via EROD assay) [1]. Importantly, CH-223191 does not directly inactivate cytochrome P450 enzymes, indicating that its inhibitory effects are entirely mediated at the transcriptional level [1].
In vivo, CH-223191 demonstrates significant chemopreventive efficacy against TCDD-induced toxicity. In mice treated with TCDD, oral administration of CH-223191 suppressed hepatic CYP1A1 induction by approximately 75% [1]. Furthermore, it significantly prevented TCDD-induced fatty degeneration of the liver (intrahepatocyte lipid accumulation) and reduced elevated plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), which are classical markers of liver toxicity [1]. CH-223191 also successfully prevented TCDD-induced wasting syndrome, allowing treated mice to maintain normal weight gain compared to the severe weight loss observed in mice exposed to TCDD alone [1].
In addition to its protective effects against xenobiotic toxicity, CH-223191 has been utilized to study the endogenous role of AhR in development. During the spontaneous differentiation of embryonic stem (ES) cells into cardiomyocytes, treatment with CH-223191 significantly decreased the number of beating embryoid body (EB)-derived cultures without affecting overall cell survival [2]. This pharmacological inhibition mirrors the effects of AhR knockdown via shRNA, demonstrating that a homeostatic level of basal AhR signaling is strictly required for proper cardiovascular development and cardiomyocyte function [2].
3. Molecular Mechanism of Action
The primary molecular mechanism of CH-223191 is the competitive inhibition of ligand binding to the AhR. Competitive binding assays using cytosolic fractions demonstrate that CH-223191 effectively blocks the binding of [3H]TCDD to the receptor [1]. By preventing ligand binding, CH-223191 subsequently halts the downstream signaling cascade: immunocytochemistry and electrophoretic mobility shift assays (EMSA) confirm that the compound completely blocks TCDD-mediated nuclear translocation of the AhR and its subsequent binding to DNA consensus DRE sequences [1].
A defining mechanistic feature of CH-223191 is its profile as a "pure" antagonist. Unlike other known AhR antagonists (such as flavone, resveratrol, and α-naphthoflavone), which can stimulate AhR-dependent transcription in the absence of TCDD at high concentrations, CH-223191 elicits absolutely no AhR-activating (agonistic) activity at concentrations up to 100 μM [1]. Furthermore, while compounds like flavone and resveratrol possess high affinity for the estrogen receptor and can potentiate 17β-estradiol effects, CH-223191 shows no effect on estrogen receptor-driven transcription, thereby minimizing the risk of estrogen-related adverse effects such as cellular proliferation in breast cancer models [1].
4. Structure-Activity Relationship (SAR)
CH-223191 was discovered through a high-throughput screening of approximately 10,000 synthetic compounds using a HepG2 cell line stably transfected with a DRE-controlled luciferase reporter gene [1]. Structurally, it is identified as 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide [1].
While an exhaustive functional group SAR was not detailed in the provided literature, the structural divergence of CH-223191 from naturally occurring flavonoids and stilbenes (e.g., flavone, resveratrol, curcumin, indole-3-carbinol, luteolin) is critical to its unique activity profile. The screening process specifically excluded hit compounds that exhibited baseline luciferase induction [1]. As a result, CH-223191 emerged as the most potent inhibitor of TCDD-induced AhR activity, boasting an IC50 of 0.03 ± 0.005 μM [1]. Its synthetic pyrazole-carboxamide scaffold provides superior inhibitory potency compared to natural AhR antagonists and uniquely strips away the dual AhR-agonist and estrogen-receptor-agonist liabilities inherent to the planar, polyphenolic structures of many natural AhR modulators [1].
5. Current Limitations
Despite its promising profile, the current understanding and application of CH-223191 face several limitations. First, the evidence supporting the non-toxic nature of CH-223191 in vivo is preliminary and restricted to short-term outcomes (e.g., 25-day studies in mice) [1]. For any potential medical or chemopreventive application, comprehensive safety assessments are mandatory. These must include genotoxicity assays, chronic toxicity studies, developmental toxicity studies, and lifetime carcinogenicity assays, alongside a full elucidation of its pharmacokinetic profile [1].
Second, while antagonizing AhR is beneficial for preventing dioxin-induced toxicity, complete pharmacological blockade of AhR by CH-223191 can interfere with normal physiological processes. Research on embryonic stem cells demonstrates that AhR plays a critical, ligand-independent (or endogenous ligand-driven) role in development. Treatment with CH-223191 disrupts the concerted expression of homeobox transcription factors and impairs cardiomyocyte differentiation, indicating that systemic AhR antagonism during pregnancy or early development could pose significant teratogenic risks or disrupt cardiovascular homeostasis [2].
6. Future Perspectives
CH-223191 represents a significant advancement in the pharmacological modulation of the AhR. Its status as a potent, specific, and pure antagonist makes it an invaluable molecular probe for dissecting the complex biology of the AhR. Future research should leverage CH-223191 to differentiate between the toxicological responses driven by exogenous xenobiotics (like TCDD) and the physiological responses regulated by endogenous AhR ligands during development and immune regulation [1][2].
Therapeutically, CH-223191 holds potential as a chemopreventive agent for individuals exposed to high levels of dioxin-like environmental contaminants, potentially mitigating risks of hepatotoxicity, wasting syndrome, and AhR-mediated carcinogenesis [1]. However, realizing this clinical potential will require extensive preclinical testing to establish long-term safety and pharmacokinetics. Additionally, understanding the delicate balance of AhR homeostasis—where both overactivation and over-inhibition can lead to pathology—will be crucial in determining the appropriate therapeutic windows and indications for CH-223191 [2].
